Evonile Pharma Approves Rights Issue of Up to ₹9,000 Million
Novartis India Ltd · Rights Issue · 09 Oct 2026, 12:36 am
Evonile Pharma Approves Rights Issue of Up to ₹9,000 Million Evonile Pharma Limited (formerly Novartis India Limited) approved raising funds up to ₹9,000 million via a rights issue of partly paid-up equity shares (face value ₹5 each) on 8th Oct'26, subject to regulatory and shareholder approvals via postal ballot. The Board constituted a Rights Issue Committee comprising MD & CEO Vikas Gupta, Non-Executive Director Dr. Jagriti Gupta, and Independent Director Shashank Sinha to determine key terms, including issue size, entitlement ratio, issue price, and record date. Additionally, the company launched its new corporate website.
Original exchange filing (PDF)
More announcements from Novartis India Ltd
- Transcript of the Earnings Call held on Wednesday, November 04, 2026. · 06 Nov 2026
- Submission of the Letter of Offer in connection with the proposed Rights Issue of the Partly Paid-up Equity Shares of the Company. · 06 Nov 2026
- Intimation is hereby given that the record date for determining the rights entitlement for the Rights Issue of partly paid-up shares of the Company shall be Wednesday, November 11, 2026. · 05 Nov 2026
- Outcome of the Board Meeting held today i.e. November 04, 2026 · 05 Nov 2026
- Outcome of the meeting of the Rights Issue Committee held today i.e. November 04, 2026 · 05 Nov 2026
- Intimation of the Audio Recording of the Earnings Call for the Unaudited Financial Results for the quarter and half year ended September 30, 2026, held today i.e. on Wednesday, November 04, 2026. · 04 Nov 2026
- Intimation of the Integrated Unaudited Financial Results for the quarter and half year ended September 30, 2026. · 04 Nov 2026
- Press Release - Unaudited Financial Results for the quarter and half year ended September 30, 2026. · 04 Nov 2026
